Want to see CLYM full AI Analyst Report?

Climb Bio (CLYM) Price & Analysis

717 Followers

CLYM Stock Chart & Stats

$9.16

-$0.15(-7.18%)

At close: Jan 08 4:00 PM EST

$9.16

-$0.15(-7.18%)

Day’s Range― - ―

52-Week Range$1.35 - $14.42

Previous CloseN/A

Volume51.97K

Average Volume (3M)1.52M

Market Cap

$791.37M

Enterprise Value$765.33M

Total Cash (Recent Filing)$109.56M

Total Debt (Recent Filing)$479.00K

Price to Earnings (P/E)―

Beta1.49

Next Earnings

Aug 18, 2026

EPS Estimate

-0.21

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.78

Shares Outstanding57,263,023

10 Day Avg. Volume1,857,585

30 Day Avg. Volume1,518,354

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)1.69

Price to Sales (P/S)0.00

P/FCF Ratio-4.97

Enterprise Value/Market Cap0.97

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-7.22K

Enterprise Value/Ebitda-14.53

Forecast

1Y Price Target

$21.56

Price Target Upside135.32% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-0.87

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Minimal Debt On Balance SheetA very low debt load materially reduces solvency and leverage risk for a pre-revenue biotech, giving management flexibility to fund development through equity or selective partnerships without heavy interest burdens. This structural strength supports execution across multi-year clinical programs.

Material Equity Financings Bolstering RunwayThe combination of a $110M private placement and a $100M at‑the‑market facility meaningfully extends cash runway, lowering near-term solvency risk and allowing continued clinical progress. Durable impact: more time to reach value-driving trial readouts before runway-driven distress.

Encouraging Early Clinical And Regulatory ProgressPositive Phase 1b/2a signals (safety, durable activity in ITP) plus translational modeling and tolerability for CLYM116 support differentiated dosing and indication breadth. Fast Track for pMN and multi‑indication programs increase the probability of meaningful, durable clinical value creation if later‑stage trials confirm efficacy.

Bears Say

Pre‑revenue With Persistent LossesBeing entirely pre‑revenue means the company has no product cash flows to absorb R&D and SG&A, leaving value and long‑term margin prospects unproven. Persistent net losses imply the business model has yet to translate pipeline progress into recurring revenues, sustaining funding dependence for months to years.

Elevated And Growing Cash BurnCash burn increased materially in 2025 and remains elevated, meaning the company consumes cash at a high rate relative to existing resources. Because net losses largely convert into real cash outflows, this structural cash burn heightens the frequency and size of future financings and pressures strategic flexibility.

Ongoing Dilution And Equity Overhang RiskRepeated large equity raises and an expanded equity plan institutionalize dilution risk, reducing existing shareholders' ownership and potential per‑share upside. Structurally, reliance on equity issuance to fund trials can depress returns on equity and complicate long‑term capital allocation choices.

Climb Bio News

Climb Bio Appoints Breanna O’Reilly to Board

Climb Bio ( ($CLYM) ) has issued an announcement. On June 29, 2026, Climb Bio, Inc. announced that...

10d ago

CLYM

Climb Bio Buy Rating Reiterated as Advancing Pipeline Supports Maintained $20 Price Target

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Climb Bio, with...

18d ago

CLYM

Climb Bio Establishes New At-the-Market Equity Program

Climb Bio ( ($CLYM) ) has provided an announcement. On June 12, 2026, Climb Bio, Inc. entered into...

29d ago

CLYM

Climb Bio price target raised to $20 from $19 at BTIG

BTIG analyst Julian Harrison raised the firm’s price target on Climb Bio (CLYM) to $20 from $19 and...

1M ago

CLYM

Climb Bio announces initial data from budoprutug study at EHA

Climb Bio (CLYM) announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating...

1M ago

CLYM

Climb Bio Reports Encouraging Early Budoprutug ITP Data

Climb Bio ( ($CLYM) ) has shared an update. On June 11, 2026, Climb Bio, Inc. reported initial...

1M ago

CLYM

Climb Bio Shareholders Approve Equity Plan Amendment, Reelect Directors

Climb Bio ( ($CLYM) ) has provided an announcement. At Climb Bio’s 2026 Annual Meeting of Stockholders held...

1M ago

CLYM

Climb Bio initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Climb Bio (CLYM) with a Buy rating and $35 price target. Lead asset budoprutug...

1M ago

AMGN

CLYM

Julian Harrison Reiterates Buy on CLYM116, Maintains $19 Price Target on Best-in-Class IgAN Potential

Analyst Julian Harrison of BTIG maintained a Buy rating on Climb Bio, retaining the price target of $19.00....

1M ago

CLYM

Climb Bio Reports Positive Early-Stage Data for CLYM116

An update from Climb Bio ( ($CLYM) ) is now available. On June 5, 2026, Climb Bio reported...

1M ago

CLYM

Climb Bio registers to sell 11.59M shares of common stock for holders

This filing relates to the offer and sale from time to time by the selling stockholder of up...

1M ago

CLYM

Climb Bio price target raised to $20 from $15 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb Bio (CLYM) to $20 from $15...

2M ago

CLYM

Climb Bio price target raised to $17 from $15 at Wedbush

Wedbush raised the firm’s price target on Climb Bio (CLYM) to $17 from $15 and keeps an Outperform...

2M ago

CLYM

Climb Bio reports Q1 EPS (20c), consensus (31c)

“During the first quarter, we continued to execute on a focused development strategy aimed at generating clear clinical...

2M ago

CLYM

CLYM FAQ

What was Climb Bio, Inc.’s price range in the past 12 months?

Climb Bio, Inc. lowest stock price was $1.35 and its highest was $14.41 in the past 12 months.

What is Climb Bio, Inc.’s market cap?

Climb Bio, Inc.’s market cap is $791.37M.

When is Climb Bio, Inc.’s upcoming earnings report date?

Climb Bio, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 37 days.

How were Climb Bio, Inc.’s earnings last quarter?

Climb Bio, Inc. released its earnings results on May 07, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.088.

Is Climb Bio, Inc. overvalued?

According to Wall Street analysts Climb Bio, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Climb Bio, Inc. pay dividends?

Climb Bio, Inc. does not currently pay dividends.

What is Climb Bio, Inc.’s EPS estimate?

Climb Bio, Inc.’s EPS estimate is -0.21.

How many shares outstanding does Climb Bio, Inc. have?

Climb Bio, Inc. has 57,263,023 shares outstanding.

What happened to Climb Bio, Inc.’s price movement after its last earnings report?

Climb Bio, Inc. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went down -2.537%.

Which hedge fund is a major shareholder of Climb Bio, Inc.?

Currently, no hedge funds are holding shares in CLYM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Climb Bio Stock Smart Score

Outperform

Fundamentals

Return on Equity

-31.46%

Trailing 12-Months

Asset Growth

-24.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Climb Bio, Inc.

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Climb Bio (CLYM) Earnings & Revenues

Historic Earnings Reports

CLYM Stock 12 Month Forecast

Average Price Target

$21.56

▲(135.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","18":"$18","27":"$27","36":"$36"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.555555555555557,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,9,18,27,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.29,14.959999999999999,16.63,18.3,19.97,21.64,23.310000000000002,24.98,26.65,28.32,29.990000000000002,31.66,33.33,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.29,13.925811965811965,14.56162393162393,15.197435897435897,15.833247863247863,16.46905982905983,17.104871794871794,17.740683760683762,18.376495726495726,19.012307692307694,19.648119658119658,20.283931623931625,20.91974358974359,{"y":21.555555555555557,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.29,13.575384615384614,13.86076923076923,14.146153846153846,14.43153846153846,14.716923076923077,15.002307692307692,15.287692307692307,15.573076923076922,15.858461538461539,16.143846153846155,16.42923076923077,16.714615384615385,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.73,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.95,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.91,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.29,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >